COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04552704
Recruitment Status : Recruiting
First Posted : September 17, 2020
Last Update Posted : November 12, 2020
National Cancer Institute (NCI)
OncoImmune, Inc.
Information provided by (Responsible Party):
Tianhong Li, University of California, Davis

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : June 1, 2023